Impact of ⁶⁸Ga-PSMA PET/CT on Survival and Management in Prostate Cancer

Title:Impact of ⁶⁸Ga-PSMA PET/CT on Survival and Management in Prostate Cancer

Volume: 20

Author(s): Efnan Algın, Berna Okudan, Yusuf Açıkgöz, Haluk Sayan, Öznur Bal and Bedri Seven*

Affiliation:

• Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, University of Amasya, Amasya, Turkey

Keywords: ⁶⁸Ga-PSMA, PET/CT, Survival, Impact, Management change, Prostate cancer.

Abstract:

Background: ⁶⁸Ga-labeled prostate-specific membrane antigen positron emission tomography-computed tomography (⁶⁸Ga-PSMA PET/CT) has led to altered treatment plans for prostate cancer (PCa) patients.

Objective: This study aimed to investigate the impact of ⁶⁸Ga-PSMA PET/CT on overall survival (OS) and management in PCa.

Methods: Consecutive 100 patients who had ⁶⁸Ga-PSMA PET/CT and conventional imaging (CI) were included in this retrospective study. Disease stages and treatment plans according to both CI and ⁶⁸Ga-PSMA PET/CT were compared. The effect of ⁶⁸Ga-PSMA PET/CT on OS was assessed.

Results: After ⁶⁸Ga-PSMA PET/CT, the stage changed in 64 patients (64%). By the reason of ⁶⁸Ga-PSMA PET/CT findings, treatment plans based on CI were changed in 73 patients (73%). According to the ROC analysis, patients with a PSA value below 8 had higher rates of change in staging (p<0.0001) and treatment (p=0.034). Both a PSA below 8 (OR 8.79 95% CI (2.72-28.43), p<0.001), and having a hormone-sensitive disease at the time of imaging (OR 5.6 95% CI (1.35-23.08), p=0.017) were significant independent factors predicting change in staging with ⁶⁸Ga-PSMA PET/CT. The results of a phi correlation coefficient analysis showed a significant relationship between therapy and changes in staging (Φ=0.638, p<0.0001). Two-year OS was statistically different in hormone-sensitive patients with and without treatment change (95% vs 81%, p=0.006).

Conclusion: ⁶⁸Ga-PSMA PET/CT has the effect of changing the treatment in 73% of PCa patients. There is a positive correlation between the changes in staging and treatment. Survival of hormone sensitive patients has improved due to treatment changes based on PET/CT findings.

Cite this article as:

Algın Efnan, Okudan Berna, Açıkgöz Yusuf, Sayan Haluk, Bal Öznur and Seven Bedri*, Impact of ⁶⁸Ga-PSMA PET/CT on Survival and Management in Prostate Cancer, Current Medical Imaging 2024; 20 : e15734056276494 . https://dx.doi.org/10.2174/0115734056276494231207101146